On the other hand, cabozantinib selectively targets hepatocyte growth factor receptors (HGFR/MET), VEGFR2, and RET that promote invasive growth and angiogenesis in MTC; similarly to vandetanib, it showed higher mPFS than the placebo in the EXAM trial (11.2 vs. 4.0 months, hazard ratio, 0.28; 95% CI, 0.19–0.40; p < 0.001) [189]. The gene discussed is KDR; the disease is medullary thyroid gland carcinoma.